164 related articles for article (PubMed ID: 34302770)
1. Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period.
Suasnábar S; Olivera LV; Arias E; Bizai ML; Bottasso O; Arias E; Fabbro D
Acta Trop; 2021 Oct; 222():106050. PubMed ID: 34302770
[TBL] [Abstract][Full Text] [Related]
2. Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study.
Colantonio LD; Prado N; Segura EL; Sosa-Estani S
PLoS Negl Trop Dis; 2016 May; 10(5):e0004651. PubMed ID: 27158908
[TBL] [Abstract][Full Text] [Related]
3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
4. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
5. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.
Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA
Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245
[TBL] [Abstract][Full Text] [Related]
6. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.
González NL; Moscatelli G; Moroni S; Ballering G; Jurado L; Falk N; Bochoeyer A; Goldsman A; Grippo M; Freilij H; Garcia Bournissen F; Chatelain E; Altcheh J
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010968. PubMed ID: 36534647
[TBL] [Abstract][Full Text] [Related]
7. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
[TBL] [Abstract][Full Text] [Related]
8. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas.
Fabbro DL; Danesi E; Olivera V; Codebó MO; Denner S; Heredia C; Streiger M; Sosa-Estani S
PLoS Negl Trop Dis; 2014 Nov; 8(11):e3312. PubMed ID: 25411847
[TBL] [Abstract][Full Text] [Related]
9. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.
Fabbro D; Velazquez E; Bizai ML; Denner S; Olivera V; Arias E; Pravia C; Ruiz AM
Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740013
[TBL] [Abstract][Full Text] [Related]
11. Chagas cardiomyopathy associated with serological cure after trypanocidal treatment during childhood.
Fernández ML; Hernández Y; Scollo K; Esteva MI; Riarte AR; Prado NG
Rev Soc Bras Med Trop; 2018; 51(4):557-559. PubMed ID: 30133646
[TBL] [Abstract][Full Text] [Related]
12. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
Gallerano RR; Sosa RR
Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase].
Silveira CA; Castillo E; Castro C
Rev Soc Bras Med Trop; 2000; 33(2):191-6. PubMed ID: 10881133
[TBL] [Abstract][Full Text] [Related]
16. [Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina].
Streiger ML; del Barco ML; Fabbro DL; Arias ED; Amicone NA
Rev Soc Bras Med Trop; 2004; 37(5):365-75. PubMed ID: 15361952
[TBL] [Abstract][Full Text] [Related]
17. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
[TBL] [Abstract][Full Text] [Related]
18. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
Murcia L; Carrilero B; Albajar Viñas P; Segovia M
Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
[No Abstract] [Full Text] [Related]
19. Cardiac Evaluation in the Acute Phase of Chagas' Disease with Post-Treatment Evolution in Patients Attended in the State of Amazonas, Brazil.
Ortiz JV; Pereira BVM; Couceiro KDN; Silva MRHDSE; Doria SS; Silva PRLD; Lira EDF; Guerra MDGVB; Guerra JAO; Ferreira JMBB
Arq Bras Cardiol; 2019 Mar; 112(3):240-246. PubMed ID: 30916205
[TBL] [Abstract][Full Text] [Related]
20. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
Álvarez MG; Ramírez JC; Bertocchi G; Fernández M; Hernández Y; Lococo B; Lopez-Albizu C; Schijman A; Cura C; Abril M; Laucella S; Tarleton RL; Natale MA; Castro Eiro M; Sosa-Estani S; Viotti R
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
